Compare drug alternatives
Incruse Ellipta ® Alternatives
Incruse Ellipta ®(Umeclidinium) | Yupelri ®(Revefenacin) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | |
Annual Cap | |
$6,660. Learn more. | |
Assistance Expiration | |
Calendar year. Learn more. | |
Generics | |
Lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common adverse reactions (incidence ≥2% and more common than
placebo) include nasopharyngitis, upper respiratory tract infection, cough,
arthralgia.. Learn more. | Most common adverse reactions (incidence greater than or equal to 2% and more common than placebo) include cough, nasopharyngitis, upper respiratory tract infection, headache, and back pain.. Learn more. |
Mechanism of Actions (MoA) | |
Anticholinergics. Learn more. | Anticholinergics. Learn more. |
Special Populations | |
8.1 Pregnancy Risk Summary Insufficient data are available on the use of umeclidinium in pregnant women to determine a drug-associated risk. Animal studies with pregnant rats and rabbits, exposed to umeclidinium through inhalation or subcutaneous routes, showed no adverse effects on embryofetal development at exposures approximately 50 and 200 times, respectively, the human exposure at the maximum recommended daily inhaled dose (MRHDID). 8.2 Lactation Risk Summary There is no information regarding the presence of umeclidinium in human milk, its effects on breastfed infants, or its impact on milk production. Umeclidinium was detected in the plasma of offspring from lactating rats treated with umeclidinium, suggesting its presence in maternal milk. The decision to breastfeed should consider the benefits of breastfeeding along with the clinical need for INCRUSE ELLIPTA, weighing potential effects on the breastfed child from umeclidinium or the maternal condition. 8.4 Pediatric Use INCRUSE ELLIPTA is not approved for use in children, and its safety and efficacy in pediatric patients have not been established. 8.5 Geriatric Use Available data do not suggest the need for dosage adjustment of INCRUSE ELLIPTA in geriatric patients. However, some older individuals may exhibit greater sensitivity, although no overall differences in safety or effectiveness were observed in clinical trials between elderly and younger subjects. 8.6 Hepatic Impairment Patients with moderate hepatic impairment (Child-Pugh score of 7-9) did not show relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. Studies in subjects with severe hepatic impairment have not been conducted. 8.7 Renal Impairment Patients with severe renal impairment (CrCl <30 mL/min) did not exhibit relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. No dosage adjustment is required for patients with renal impairment. | 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with YUPELRI in pregnant women. If a woman becomes pregnant while taking YUPELRI, it is advisable to contact their physician. Animal reproduction studies showed no evidence of fetal harm at exposures up to 209 times the maximum recommended human dose. 8.2 Lactation Risk Summary There is no information available regarding the presence of revefenacin in human milk or its effects on breastfed infants. However, revefenacin was found in the milk of lactating rats. The decision to breastfeed should consider both the benefits of breastfeeding and the clinical need for YUPELRI, weighing potential effects on the infant from YUPELRI or the mother's underlying condition. 8.4 Pediatric Use The safety and effectiveness of YUPELRI have not been established in pediatric patients, and it is not indicated for use in children. 8.5 Geriatric Use Available data indicate no need for dosage adjustment in geriatric patients. Clinical trials included subjects aged 65 years and older, with no overall differences in safety or effectiveness observed between these subjects and younger subjects. 8.6 Hepatic Impairment Revefenacin exposure remains unchanged in subjects with hepatic impairment, while the active metabolite's exposure increases. YUPELRI's safety has not been evaluated in COPD patients with hepatic impairment and is not recommended for patients with any degree of hepatic impairment. 8.7 Renal Impairment No dosage adjustment is necessary for patients with renal impairment. However, COPD patients with severe renal impairment should be monitored for systemic antimuscarinic side effects. |